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Summary The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in
advanced breast cancer was assessed by performing an overview employing summary statistics derived from
published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens
in which dox was replaced by one or more compounds. Trials were selected which published data on survival,
time to treatment failure and response rate. This study suggests that dox confers advantages on all of these
endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox.
The primary aim of chemotherapy in advanced breast cancer
is improvement in quality of life and in clinical trials the
duration of successful palliation is assumed to be the time to
treatment failure. Response rate, duration of response and
toxicity are considered to be secondary endpoints which have
traditionally been emphasised in the assessment of treatment
value, but though linked to quality of life they are not
reliable surrogate measures. Survival has been an endpoint
only of limited interest and only rarely have Randomised
Controlled Trials (RCT's) demonstrated a difference.
Many physicians regard doxorubicin hydrochloride (dox)
as an important part of therapy. CALGB(US) for example,
have entered more than 1,500 patients into a trial comparing
three different doses of CAF (Henderson, 1991). The value of
dox in advanced breast cancer is the subject of debate which
centres on the trade off between toxicity and efficacy.
Belanger et al. (1991) reported a survey of treatment patterns
in which five hypothetical breast cancer patients were presen-
ted to American oncologists. One such case was an oestrogen
receptor negative woman with metastatic breast cancer and
minimal symptoms. Seventy-one per cent of physicians stated
they would try to enter such a patient into a trial in which
both arms contained CAF. In the hypothetical case of a node
positive, oestrogen receptor negative postmenopausal woman
with early breast cancer, 79% of physicians stated they
would prescribe adjuvant chemotherapy in such a situation.
Eighty-three per cent of physicians stated they would offer
such a patient entry into a randomised trial of CMF vs CAF.
The assessment of survival differences in RCT's in
advanced disease may be confounded by the fact that
patients may be crossed over onto the second regimen after
failing on the first regimen received (see for example Madsen
et al. (1991)). This may give rise to the anomaly that treat-
ment decisions which are influenced by the existence or
otherwise of a survival benefit may be made on the basis of
randomised trials in which patients in both arms received all
of the agents being assessed, though the physician making
the decision may not intend to give all of the agents during
the disease process. However, differences in outcome in
RCT's of chemotherapy in advanced disease are unlikely to
be large, since commonly two regimens of similar potency are
compared. Quantitative reviews which combine results from
different published studies, or preferably full overviews,
therefore have an important role in detecting comparatively
small treatment effects.
In a previous paper we addressed the question of the effect
of chemotherapy on survival in advanced breast cancer
indirectly by correlating differences in response rates in pairs
of arms of randomised trials with differences in median
survival A'Hern et al. (1988). It was not possible to assess the
effect of chemotherapy directly because there are not ran-
domised trials comparing treatment with chemotherapy with
no treatment. This study suggested that improved survival
was associated with increased response rates. If this effect
had been solely due to chance imbalances in the proportion
of good prognosis patients between arms, it would be
expected to be greater in smaller trials, however, this could
not be shown to be the case. We therefore concluded that
chemotherapy may improve survival. The methodology des-
cribed below has enabled us to test whether a particular
agent, dox, associated with higher response rates is also
associated with improved survival. We have investigated the
role of dox in Cooper-type regimens (i.e. regimens with a
combination of agents including some or all of the following:
cyclophosphamide, methotrexate, 5-FU, vincristine and pred-
nisolone) in advanced breast cancer by undertaking an over-
view employing summary statistics derived from published
papers of randomised clinical trials assessing time to treat-
ment failure, response rates and survival, in studies which
published all these endpoints.
Materials and methods
This study only employed data from randomised trials. A
pure assessment of the addition of dox to a Cooper regimen
would be made by examining randomised trials in which dox
was given with other Cooper drugs and compared against the
same drugs without dox. However, we were unable to iden-
tify any such published trials. The question most commonly
addressed in assessing the role of dox in Cooper type
regimens is the role of dox as a replacement for one or more
drugs.
Randomised trials were identified by communication with
colleagues and by undertaking a computerised literature
search using Cancer Lit, in all these trials patients were
analysed according to their allocated treatment. This search
identified five trials which had been published in more than
simply abstract form which included data on response rates,
the time to treatment failure and survival. We are aware of
other trials which we have not included because of lack of
data on at least one of these endpoints. In one trial, Tormey
et al. (1984), we have only compared the arms given intermit-
tent treatment, the arm given continuous CMFVP was ex-
cluded because it could not be compared with an arm given
continuous CAFVP.
Statistical methods
Response rates were combined using the Mantel-Haenszel
method, (Mantel et al., 1959) and the method described
below was used to combine log hazard ratios. Both these
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methods do not allow differences between trials to contribute
to the standard error of the overall estimate of the treatment
effect. An alternative approach is to use techniques in which
it is assumed that each study has a true effect which it
estimates, the combined effect across studies is then based on
the estimates of the true effect for each study (Berlin, 1989).
The trials are thus considered to be a random sample of all
possible trials which address the comparison of interest.
Reviews of the type undertaken in this paper are best cons-
trued as giving qualitative rather than quantitative results
(Thompson & Pocock, 1991).
The method of comparing time to treatment failure and
survival curves was based on estimation of the hazard ratio
and its variance from the published curves and the P-value
for their comparison. A worked example is given in Appen-
dix I. The hazard ratio and its variance were not given
directly in any of the published papers. These hazard ratios
were then combined across studies if a test for heterogeneity
between studies was non-significant. Curves representing time
to treatment failure were combined whether or not they
included death as an endpoint, in some cases this was not
explicitly stated.
If the proportional hazards model is assumed to apply
then the hazard ratio (HR) can be estimated from F1(t) =
(F2(t))HR. Thus HR = ln(Fj(t))/ln(F2(t)) where FI(t) and F2(t)
are the values of the survivor functions in the two arms being
compared at time t. The hazard ratio for each trial was
estimated over each 6 month period and a weighted average
(of the log hazard ratio) taken where the weighting factor for
each period was the estimated number of deaths.
The number of deaths can be used as a weighting factor
because the variance of the log hazard ratio will be approx-
imately inversely proportional to the number of events. If,
for example, there was no censoring and the event rate
followed an exponential distribution, the log hazard ratio
would have a variance estimated by (d1 + d2)/dld2 where dI
and d2 are the number of events in the groups being com-
pared (Kalbfleisch & Prentice, 1980). Assuming there are
approximately the same number of events (d) in each group
the variance then becomes 2/d. The reciprocal of this is then
half the number of events and the number of events can
therefore be used as a weighting factor. The number of
events has been calculated from the original number at risk
and the change in the proportion event free within each
interval.
For simplicity, it was assumed there was no censoring, thus
slightly too much weight will have been attached to the
hazard ratios estimated from the right of the curves. Appen-
dix I includes a recalculation of the example assuming 5%
censoring in each interval. After tests for heterogeneity had
been performed (Armitage & Berry, 1990), log hazard ratios
were then combined across trials using an inverse variance
weighting.
Where P-values were not given exactly the highest estimate
was used e.g. P<0.01 was taken as P= 0.01. In some in-
stances Gehan's test had been used to compare curves, the
P-value from this test was employed although it may not
always be the same as that derived under the proportional
hazards assumption. In order to summarise the data the
average per cent failure free, response rates and per cent
surviving were calculated as weighted averages from the indi-
vidual trials.
Results
No relevant differences in patient characteristics between
studies were noted. The results for individual trials are shown
graphically in Figure 1. The overall hazard ratio for the time
to treatment failure was 0.69 (95% CI: 0.59-0.81, P<0.001)
and for survival was 0.78 (0.67-0.90, P<0.001), both fav-
ouring the dox containing arm. Figures 2 and 3 show the per
cent surviving and failure free. The odds of response was 0.56
(0.43-0.73, P<0.001): this also favoured dox. The overall
survival and time to treatment failure curves are shown in
Figures 2 and 3.
Discussion
These results suggest that the inclusion ofdox in Cooper type
regimen increases the odds of response, reduces the hazard of
dying by 22% (95% CI: 10%-33%), and reduces the hazard
of treatment failure by 31% (95% CI: 19%-41%). This is
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Figure 1 Diagrams showing odds ratios for response rates, and estimates of failure free survival and survival in randomised trials
examining the substitution with doxorubicin in Cooper type regimens. The overall estimates are shown as diamonds, the width of
the diamonds denoting a 95% confidence limit. For the individual trials the area of the boxes is proportional to the weight given to
each trial, the horizontal lines denote 95% confidence intervals.
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It is important to note that this study do
ual patient data or unpublished studies, th
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from the shortcoming that only selected
published and this publication bias may d
ment of treatment effect. It has been I
positive studies are more likely to be publis
ones; it is difficult, however, to propose ho
should be defined in the context of the que
this paper. A further disadvantage of not using individual
patient data is that other prognostic factors cannot form part
n containing arm of the analysis. It should also be noted that within the trials
Incontainng arm reviewed in this study the largest trial compared aggressively
ubicin administered CAF with low dose intermittently administered
CMFVP (Smalley et al.), dose intensity may therefore also be
2= a confounding factor.
P<0.001 The largest randomised clinical trial (known to the au- thors) addressing the value of the inclusion of dox compares
CAF and CMF (Madsen et al., 1991) in a randomised trial.
- = ---- This study, which was undertaken by the Danish Breast
Cancer Cooperative Group and included 416 patients, has
not been included in this paper because it has only been
published in abstract form. The published results are in
30 36 agreement with the results of this study: time to progressive
disease was better in the CAF arm (Hazard Ratio 0.6, 95%
CI: 0.4-0.9, P<0.01), the odds ratio for response favoured
CAF (2.18 95% CI: 1.43-3.33) (P<0.001) and an estimate
smrvival which has for the hazard ratio for survival was 0.80, 95% CI: 0.65-
*om the individual 1.05. (P<0.10).
It has long been recognised in cancer research that large
randomised trials are needed to detect differences in outcome
that are medically plausible and that trial size is frequently
far from ideal. Regrettably only a small percentage of
patients are actually entered into trials despite the fact that
cin containing arm many unanswered therapeutic questions still exist. Improved
wrubicin accrual of patients into trials and increased collaboration
between groups would help to overcome this problem. In
addition, parallel studies leading to overviews and two-stage
Phase III studies (Freedman, 1989) can be considered. The
recognition that a trial which a group wishes to undertake
will not yield a worthwhile evaluation of the treatments being
assessed can be an obstacle to research. If other groups are
undertaking trials addressing a similar question, however, the
outcomes from such parallel studies can be combined using
overview methodologies, and this will increase the probability
30 36 of a meaningful conclusion. This paper emphasises the value
of parallel studies in advanced cancer. It also reinforces the
start need for information based on treatment as allocated to be
published on the endpoints of response rate, response dura- ring overall failure tion, time to disease progression and survival. These end-
tage from the indi- points could be mandatory before a trial was to be con-
sidered for publication. In addition, ethics committees could
demand that trials are registered with cancer trials registries
so that they will be traceable by groups wishing to perform
1 ofapproximately overviews.
ncrease in median The typical route of development for a drug or regimen is
ths. These benefits to progress from use in advanced disease to early disease
toxicity associated once efficacy has been confirmed. A benefit of overviews in
able I. In three of advanced disease is that they may help to identify com-
vining arm showed pounds or regimens that may be worthy of testing in early
disease. An overview of randomised clinical trials of chemo-
es not use individ- therapy in advanced ovarian cancer, for example, aided the
e latter may often choice of regimens for use in early disease (Advanced
y therefore suffer Ovarian Cancer Trialist Group (1991)). In breast cancer an
studies might be increased cytotoxic effect measured in terms of tumour
listort any assess- regression in advanced disease may potentially also achieve a
hypothesised that greater cytotoxic effect and greater ovarian suppression in
;hed than negative patients with early disease. The use of reviews ofendpoints in
w a positive study advanced disease will enable choices about the use of regi-
stion addressed in mens in early disease to be made on more objective criteria.
Table I A qualitative summary of toxicity results in the trials contributing to this analysis
Nausea Toxicity Mucositis
and IStomatitis
Vomiting Leucopaenia Alopecia Cardiotoxicity /Oral
Tormey et al. = D*
Aisner et al. =
Bull et al. D* D* D*=
Cummings et al. D* D
Smalley et al. D* D* D*
=similar; A: Doxorubicin containing arm worse; N: Non-doxorubicin arm worse; blank = not
mentioned; *Denotes statistical significance.
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Appendix I
Calculation of summary statistics from each trial and their combina-
tion across trials.
(Formulae are given in italics. Please note that the values given in
this example were computer generated, if you work through this
example your figures may differ slightly because of rounding
differences).
(i) Calculation of the log hazard ratio and its variance from pub-
lished survival curves and the P-value for their comparison.
Example: Tormey et al. (1984), CAFVP vs CMFVP,
Endpoint: Survival
The probabilities of being alive (extracted from the curves in the
published paper) are approximately
Months after treatment
0 6 12 18 ... 42
CAFVP 1.0 0.81 0.65 0.50 . 0.23
CMFVP 1.0 0.76 0.52 0.37 . . . 0.09
CAFVP 1.0 a(J) a(2) a(3) . . . a(7)
CMFVP 1.0 b(l) b(2) b(3) . . . b(7)
Thus the probability of remaining alive within each period is
CAFVP 1.0 0.81 0.80 0.77 . . . 0.75
CMFVP 1.0 0.76 0.68 0.71 . . . 0.59
CAFVP 1.0 A(J)=a(J) A(2)=a(2) A(7)=a(7)
1.0 a(l) A(6)
CMFVP 1.0 B(l)=b(J) B(2) =b(2) . . . B(7) =b(7
1.0 b(l) b(6)
From which the estimated log hazard ratio within each period can be
calculated
LH - 0.265 - 0.570 . . . - 0.60
LH(I) = In In(A(l)) . . LH(7) = In In(A(7)) ...
In(B(I)) In(B(7))
The estimated deaths within each period, ignoring censoring, are
Deaths 46.2 42.7 . . 15
D(J) = D(2) = D(7) =
CAFVP NJ*(J-a(l)) NJ*(a(1)-a(2)) Nl*(a(6)-a(7))
+ + +
CMFVP N2*(1-b(l)) N2*(b(1)-b(2)) N2*(b(6)-b(7))
where NI = No of CAFVP patients (107) and N2 = No of CMFVP
patients (109).
An estimate of the overall Log Hazard Ratio is then
LH = - 0.454
= D(1)*LH(J) + D(2)*LH(2) + D(7)*LH(7)
TD TD TD
where TD is the estimated total deaths = 181
TD = D(l) + D(2) + D(7)
The P-value for the comparison of the curves is
P = 0.01 (from the published paper)
this corresponds to a 2-sided
standardised normal deviate of 2.58 (z)
The standard error of LH (which is always positive) is then
approximately
LH=0.176 (s) and its variance is 0.031 (s2)
z
(ii) Combining several log hazard ratios.
Suppose the above trial was the first was the first trial in a series
contributing to an overview and let the log hazard ratio calculated
above be LHR(J) and its variance V(J), a third quantity W(l), the
inverse variance weighting factor can be calculated.
If these values for five trials are
log
Hazard Ratio Variance Weight
Trial 1 - 0.45 0.031 32.2
Trial 2 - 0.43 0.044 22.6
Trial 3 -0.85 0.311 3.2
Trial 4 0.06 0.133 7.5
Trial 5 -0.16 0.009 110.0
Trial I LHR(J) V(J) W(1) = I/V(I)
Trial 2 LHR(2) V(2) W(2) = J/V(2)
Trial 3
Trial 4
Trial 5
Heterogeneity between trials can be tested by calculating
G = 4.91
G = GJ-G22/TW
which has a Chi-square distribution with 4 (Number of trials-l)
degrees of freedom (P = 0.30). If this reaches statistical significance
then there is evidence that the treatment effect differs between trials,
so calculation of a common overall treatment effect is not justified.
The terms in the above equation are given by
Gl = 15.9
GI = W(l)*(LHR(1)2) + W(2)*(LHR(2)2) +
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and
G2=-43.9
G2 = W(J)*LHR(J) + W(2)*LHR(2) +
W(5)*LHR(5)
and where TW is the total of the weights,
TW= 175.5
TW= W(J) + W(2) + W(3) ... + W(5).
The inverse variance weighted overall log hazard ratio is then
OLHR = - 0.25
OLHR = W(J)*LHR(1) + W(2)*LHR(2) + ... W(S)*LHR(5)
TW TW TW
or OLHR = G2/TW
This has variance J/TW, and its standard error (SE) is given by the
square root of J/TW. A 95% confidence interval is given by
OLHR ± (1.96*SE).
OLHR = -0.25 (-0.40 - -0.10)
Exponentiating, this gives
Overall Hazard Ratio = 0.78 (0.67-0.90)
The hypothesis that OLHR is zero, i.e. that there is no treatment
effect, can be tested by calculating the Chi-square statistic
OLHR2*TW (11.0 in this case) which is compared against a Chi
square distribution with one degree of freedom.
(iii) Allowing for censoring.
The assumption made above that there is no censoring will result in
greater weight being given to the hazard ratios calculated from the
tail of the curve than would occur in practice. Censoring might be
allowed for by assuming that a constant proportion C are censored
in each interval. This will add in an extra term to the calculation of
the number of deaths in each interval,
D(i) = (l-C)' * [NJ*(a(i-l)-a(i)) + N2*(b(i-1)-b(i)) ]
where i is the interval number.
Assuming that there is 5% censoring in each interval above, the
hazard ratio becomes 0.79 (95% CI: 0.68-0.90), there is thus little
change.